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A brief overview is provided of the bioactivity of macrolides against a range of bacterial species. Topics considered 
include the cellular pharmacokinetics of uptake and efflux of these drugs and the importance of intra- or extracellular 
and cytoplasmic or granular location on their activity. Emphasis is placed on the importance of synergy between 
macrolides and host defenses, with drug accumulation producing modification of cellular function, such as enhancement 
of phagocytosis, and exocytosis of polymorphonuclear neutrophils. Such interaction may explain the activity of such 
agents against organisms which normally inhibit fusion of phagolysosornes. 
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Macrolide antibiotics form one of the most fascinating 
families of antibacterial agents. Although they have 
been in use for more than 40 years, new therapeutic 
prospects have recently triggered a worldwide interest 
in this class [1,2]. Part of this renewal stem &om the 
exceptional ability of these agents to concentrate 
within host cells, a property which emphasizes their use 
in infections caused by facultative or obligate intra- 
cellular pathogens. This cellular accumulation may also 
m o w  cell functions, contributing to the clinical 
efficacy of macrolides. 
This paper provides a brief overview of the 
intracellular bioactivity of macrolides, as demonstrated 
in vitro in cellular models, and when possible, cor- 
relates this activity with data fiom animal models. It first 
reviews the conditions required for intracellular activity, 
as well as the peculiar cellular pharmacokinetics of 
macrolides. It then analyzes the overall activity of these 
agents in Werent models according to the cellular 
location of the pathogens (phagolysome, phagosome or 
cytoplasm). The third section and conclusion present 
hypotheses correlating antibacterial activity with 
certain momfications of host cell hct ions.  
INTRACEUULAR BIOACTIVTTY: GENERAL ASPECTS 
AND MACROLIDE CELLULAR PHARMACOKINETIGS 
The host defense system, and particularly the phago- 
cytes, can eradicate most invading pathogens. However, 
some microorganisms have evolved strategies to escape 
this kdhng activitq and thus may persist or even 
multiply within host cells. Intracellular 'parasitism' 
implies entry within host cells, including phagocytes, 
and avoidance of natural bactericidal systems either by 
inhibiting phagolysosomal fusion (Yersinia, Ehrfichia, 
Chlamydia, Mycobacterium avium, M.  tuberculosis), by 
escaping into the cytoplasm ( M .  leprae, Rickettsia, 
Listeria, Shigella), by resisting, ihb i t ing  or even using 
natural intraphagolysosomal conditions (Y pestis, 
Coxielfa, Leishmania), or lastly by triggering the 
formation of a phagosome of particular structure 
(Legioneffa, C. psittaci, Toxopfasma gondiq [3]. 
Such intracellular pathogens are in general 
protected h m  the bactericidal activity of non-cell- 
penetrating agents. Accordingly, the first conchtion for 
antibacterial agents to have intracellular bioactivity is 
their abihty to enter host cells, although many other 
factors such as the precise drug location, the pathogen 
and the host are of major importance (Table 1). There 
is abundant literature on macrolides (for review see 
Labro [4]). This review will simply compare the new 
14-membered-ring macrolides with the azalide 
azithromycin in three important aspects of cellular 
pharmacokmetics, namely cellular accumulation, efflux 
and cellular location. The chosen cell model is the 
human polymorphonuclear neutrophil (PMN) [5,6], 
whch is undoubtedly the most active factor in anti- 
infection defenses. 
The kinetics of macrolide uptake clearly differ- 
entiate two groups of drugs (Figure 1). Azithromycin 
and, to a lesser extent, dirithromycin and erythro- 
mycylamine, are accumulated by PMNs in a time- 
dependent manner, for up to  3 h with no saturation. 
Azithromycin shows the strongest accumulation, with 
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Table 1 Bioactivity of antibacterial agents: conditions for efficacy 
Drug Host Pathogen 
1. ‘Classical’ pharmacokinetics A: Reaching the target 
2. ‘Cellular’ pharmacokinetics 
Lipophilicity 
Acidic/basic nature 
Apb Infected cells 
(a) Transport and efflux h r n  
phagocytes (‘tissue-directed’ 
pharrnacokinetics) 
(b) Entry within host cells 
Transporter 
(c) Location 
a C/E (cellular-to-extracellular) concentration ratio 
exceeding 300 after 3 h. Clarithromycin, roxithro- 
mycin and, to a lesser extent erythromycin are taken 
up rapidly with a plateau at 30 to 60 min; maximal 
C/E values are about 100 for clarithromycin and 
roxithromycin and 30 for erythromycin. 
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Figure 1 Kinetics of uptake of macrolides by human 
PMNs. C/E = cellular (C) to extracellular 
(E) concentration ratio (E = 2.5 mg/L). AZI = 
azithromycin, CLA = darithromycin; DDR = dirithromycin; 
ECM = erythromycylamine; ERY = erythromycin; 
ROX = roxithmmycin. 
Macrolides also fall into two groups in efflux 
experiments (Figure 2). Azithromycin, dirithromycin 
and erythromycylamine are slowly released fiom loaded , 
Figure 2 Efflux of macrolides h m  drug-loaded PMNs. 
PMNs were incubated for 30 min in the presence of 
macrolides (2.5 mg/L); after centrifugation, drug-loaded 
PMNs were incubated in drug-he medium; at various 
times, cell samples were centrifuged and the amount of 
macrolides was determined in the cell pellet and the 
supernatant. Results are expressed as the percentage of cell- 
associated macrolides over the sum @ellet + supernatant). 
Abbreviations as in Figure 1. 
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M. avium complex, will be presented as new potential 
targets for macrolides. Last, pathogens located in the 
cytoplasm (Listeria and Rickettsia) and enteric pathogens 
wdl be mentioned as future targets of macrolide 
research. 
StBphyiococcus aureus 
Macrolides are active against phagocytosed Staph. aureus 
[7,8] in human PMNs and monocytes, and in the 
macrophage cell line 5774. In some studes, the drugs 
were equally active when added before or after 
phagocytosis [9], the effect being independent of the 
concentration (0.1-10 mg/L). In another interesting 
study, roxithromycin was not active in broth (MIC > 
128 mg/L for a clinical isolate of Staph. aureus), while 
extracellular concentrations of 2 and 16 mg/L resulted 
in a significant reduction in bacterial survival in the 
presence of PMNs (55% and 47% versus control 140%, 
after 6 h) [lo]. 
According to Meyer et al [ll], azithromycin on 
Figure 3 Cellular location of macrolides. Macrolide-loaded 
PMNs (30 min-E = 2.5 mg/L) were centrifuged. The cell 
pellet urds sonicated in the presence of 0.73 M sucrose to 
irotect granules, and after &acentrifugation percentage Staph. aureus (type 42D) in cell-6ee medium was 
enzyme and macrolide recovery in the 
determined. LDH = lactate dehydmgenase (cytoplasmic 
marker); (p-GLU: (p-glucuronidase (azurophilic granule 
marker). For other abbreviations see Figure 1. 
Pellet maximally bacteriostatic at concentrations > 5 mg/L, 
whereas concentrations greater than 1.5 mg/L were 
bactericidal for Staph. aureus ingested by monocytes. 
These data and others [12,13] point to possible synergy 
cells in antibiotic-fke medium (40-50% efflux at 60 
min), whereas about 80% of clarithromycin, roxithro- 
mycin and erythromycin is quickly released. Lastly, 
dirithromycin and azithromycin, but not erythro- 
mycylamine, are mainly concentrated within the 
granular &action of PMNs, whereas the other drugs are 
located in both the cytoplasm and granules (Figure 3). 
These results support the hypothesis that macrolide 
accumulation within host cells is partly due to trapping 
by protonation of these weak bases in aci&c cellular 
compartments such as the PMN azurophdic granule. 
Recently, we demonstrated that the entry mechanism 
of these drugs is linked to the Na+-Ca*' exchanger and 
requires extracellular Ca2+ [6]. 
INTRACELLULAR BlOACTlVlTY OF MACROLIDES 
Phagocytic and non-phagocytic cells and cell lines of 
human and animal origin have been used to study the 
intracellular bioactivity of macrolides. We review the 
data according to the cellular location of pathogens, 
choosing Staphylococcus aureus as a representative organ- 
ism which may persist, but not multiply, within host 
cells. We then look at the effects of macrolides on 
Legionella spp. and Chlamydia spp., which reside in a 
phagosome, as the emergence of these pathogens is one 
reason for the renewed interest in macrolides. Other 
between the intraphagolysosomal environment and the 
antibacterial action of macrolides. 
lntraphagosomal pathogens 
Legionella spp. 
The emergence of Legionella, a facultative intracellular 
bacterium, as an important cause of acute pneumonia 
and nosocomial infections in the 1980s was one reason 
for renewed interest in macrolides. Although erythro- 
mycin was initially considered the drug of choice in 
legionellosis, occasional failures and late response led to 
a search for more effective compounds. In an in vitro 
model using peritoneal macrophages 6om guinea pigs, 
Kitsukawa et a l  [14] compared the minimal extra- 
cellular concentration inhibiting intracellular multi- 
plication (MIEC) of L. pneumophila and compared it 
with conventional minimum inhibitory concentrations 
(MICs) of various antimicrobial drugs. p-lactams were 
highly effective in broth but not in macrophages. 
Rifampicin and quinolones were effective in both 
systems. Erythromycin was moderately active against 
extracellular and intracellular bacteria (MIC 0.125 
mg/L, MIEC 0.5 mg/L) but roxithromycin was far 
more effective intracellularly (MIC 0.0625 mg/L and 
MIEC 0.01 mg/L). 
Other authors have clearly shown the good 
intracellular bioactivity of the newer macrolides 
(roxithromycin, clarithromycin and azithromycin) in 
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human phagocytes against L. micdadei [13,15,16] and 
L. pneumophila [17], although bacteriostatic or bacteri- 
cidal activities have been described depending on the 
phagocyte used. In general, the newer macrolides 
displayed better activity than erythromycin A. This may 
be accounted for by the better cellular and tissue 
pharmacokinetics of these drugs than those of 
erythromycin A, as shown, for example, by Stamler 
et al [18] with azithromycin in both in vitro and in vivo 
models of L. pneumophila infection. As Legionella spp. 
are facultative intracellular pathogens, legionellosis may 
be both an intra- and extracellular infection. The 
overall therapeutic efficacy of antibacterial agents will 
thus depend on the complete eradication of all 
multiplying bacteria. Models which assess intracellular 
drug activity do not consider whether intracellular 
accumulation is o&et by a corresponding decrease in 
extracellular activity. 
Recently, Scaglione et al [19] described a new in 
vitro model to assess intra- and extracellular activity and 
used it to compare clarithromycin and azithromycin 
against Staph. aureus and L. pneumophila. Azithromycin 
was almost exclusively found in the intracellular 
compartment. It completely eradicated both species 
intracellularly but had no effect on extracellular 
multiplication. In contrast, clarithromycin was distri- 
buted between the two compartments (two-thirds 
intracellularly) and eradlcated both intra- and extra- 
cellular pathogens. 
Chlamydia spp. 
Chlamydia are obligate intracellular pathogens of 
phagocytic and non-phagocytic host cells. Conse- 
quently, antichlamydial activity in vitro is a mirror of 
cellular drug uptake. It is universally agreed that 
macrolides have excellent chlamydiacidal activity. 
Hammerschlag et al [20] reported MCCs (minimal 
chlamydiacidal concentrations) ranging &om 0.008 to 
0.25 mg/L with clarithromycin, azithromycin and 
erythromycin for 11 strains of C. pneumoniae. These 
MCCs compared favorably to those obtained with L- 
ofloxacin and doxycycline (0.125-0.25 mg/L). The 
MCC of roxithromycin for three laboratory strains of 
C. trachomatis (0.8 mg/L) was s d a r  to that of 
ofloxacin (1.0 mg/L) [21]. Mends et a1 [22] reported 
MCCs of 0.125 to 0.25 mg/L with roxithromycin and 
0.125 to 0.5 mg/L with erythromycin against 33 
clinical isolates of C. trachomatis. 
Roxithromycin and erythromycin are also active 
against C. psitacn' [23], with the dlsappearance of 
inclusions in McCoy cells at concentrations > 0.5 
mg/L. The macrolides were as active as minocycline 
and doxycycline and more effective than pefloxacin 
and ofloxacin. Using the macrophage cell line 5774, 
Scorneaux et al [24] have demonstrated the good 
intracellular activity of roxithromycin and erythro- 
mycin against C. trachomatis and C. pneumoniae. Less 
than 1% of cells were infected afier exposure for 60 h 
(C. trachomatis) or 74 h (C. pneumoniae) to 5 mg/L of 
each macrolide. 
Mycobacteriurn avium complex 
M. avium complex (MAC) is a common opportunistic 
pathogen, and is one of the most difficult complications 
of HIV infection to treat. MACs are characteristically 
resistant to many antituberculous drugs and major 
efforts are being made to find drug combinations or 
prophylactic regimens to overcome this resistance. 
Among drugs which provide new hopes are the new 
macrolides roxithromycin, clarithromycin and azithro- 
mycin. Bermudez and Young [25] have reported that 
although roxithromycin (2 mg/L) and azithromycin (10 
mg/L) had only slight bactericidal activity (about 20%) 
for MACs in human macrophages (4-day cultures), this 
was enhanced to 73% and 62%, respectively, in the 
presence of tumor necrosis factor (TNF) (100 U/ml). 
The triple combination (roxithromycin, TNF and 
amikacin 12 mg/L) resulted in 91% killing of intra- 
cellular MACs. Further work has pointed to the 
intracellular bactericidal activity of roxithromycin and 
clarithromycin in human macrophages and 5774 for 
MAC strains isolated fiom HIV-seropositive and HIV- 
seronegative patients, and almost complete eradication 
using the triple combination of a macrolide plus 
rifampicin plus ethambutol [26,27]. The in vitro 
activity of roxithromycin, clarithromycin and azithro- 
mycin has been correlated with therapeutic efficacy in 
animal models of infection [2&30]. Clinical trials have 
been started to assess the therapeutic and prophylactic 
efficacy of these drugs. 
Other examples of intracellular bioactivity 
Organisms located in the cytoplasm 
Some organisms (Shigelfa, Rickettsia, M. leprae, Listeria) 
have developed various ways of crossing or destroying 
the phagosomal membrane and thus escaping the 
microbicidal environment of the vacuole. Various 
authors have reported that clarithromycin is bacteri- 
cidal for M .  leprae, leading to clinical trials with this 
drug. The results of such studies are encouraging 
and have provided new strategic directions for the 
development of macrolides [31,32]. Among the more 
classical cytoplasmic pathogens, Listeria monocytogenes 
has been widely studied for its sensitivity to macrolides. 
Roxithromycin, clarithromycin, erythromycin and 
dirithromycin have intracellular bioactivity against this 
pathogen phagocytosed by human PMNs [12,13,15]. 
Recently Willot et al [33], using the 5774 model, 
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reported strong bactericidal activity of azithromycin 
and roxithromycin (10 x MIC) for this bacterial species, 
(both hemolysin producers and non-producers). Acti- 
vity was comparable to that of ciprofloxacin, whereas 
gentamicin and ampicillin were clearly ineffective. The 
few published data on the intracellular activity of 
macrolides for Rickettsia suggest that these drugs are 
marginally effective (josamycin, erythromycin) or 
ineffective (spiramycin). 
Non-conventional organisms: enteric pathogens 
Enterobacteriaceae are not usually covered by the 
spectrum of macrolides. Azithromycin has recently 
been shown to have slight activity against these 
pathogens. Two stuhes have analyzed the intracellular 
activity of this drug against phagocytosed Gram- 
negative bacilli. Willot et al [33] observed intracellular 
bactericidal activity of azithromycin for Shige2lapRxneri 
within 5774 macrophages, similar to that obtained with 
ciprofloxacin, whether or not the strain possessed the 
plasmid pWR100. Rakita et al[34] have also compared 
the intracellular activity of erythromycin and azithro- 
mycin for various Enterobacteriaceae (S. enteritidis, S. 
typhi, S. sonnei, S. dysenteriae and enteroinvasive E .  coli 
strains). Erythromycin was ineffective in broth (MICs 
8 to 64 mg/L) but was effective on phagocytosed 
pathogens, although the extracellular concentration 
tested (8 x MIC) was therapeutically irrelevant. The 
MICs of azithromycin ranged f b m  0.25 to 2 mg/L. 
Intracellular survival at an extracellular concentration 
of 8 x MIC was f b m  0.01% to 4%. For Shigella and 
Salmonella spp. the intracellular activity was greater than 
that obtained with the same azithromycin concen- 
tration in broth. 
CONCLUSIONS AND PERSPECTIVES 
This brief, and obviously incomplete, overview of the 
literature on macrolide intracellular bioactivity clearly 
shows that, largely as a result of their intracellular 
accumulation, these drugs are active against intracellular 
organisms in vitro. Several fundainental and mech- 
anistic data on how these drugs contribute to bacterial 
eradication remain to be obtained. MIC and MBCs on 
the one hand, and cellular drug accumulation and 
location on the other, may not be the only explanations 
for this activity. For instance, despite the tremendous 
cellular accumulation of azithromycin, t h i s  drug 
does not appear to be sigdicantly more active than 
clarithromycin or roxithromycin. Also intriguing is the 
fact that the actual location of various macrolide- 
sensitive pathogens (Chlamydia, Legionelfa, M. auium), 
i.e. the phagosome, is not the same as that of active 
drugs (cytoplasmic and/or granular). Furthermore, in 
various studies, intracellular activity is observed in one 
type of phagocyte but not in another. Similarly, 
intracellular activity is not observed in functionally 
deficient phagocytes. Lastly, the overall clinical efficacy 
of macrolides may not always parallel in vitro results. 
These data emphasize the need for cooperation 
between the drug and (intact) host defenses. Indeed, it 
is widely acknowledged that macrolide accumulation 
within cells, particularly phagocytes, modifies cellular 
functions in vitro and ex vivo [35]. Several aspects of 
macrolide interference with phagocyte functions have 
been unambiguously demonstrated in vitro. T h  covers 
the enhancement of phagocytosis, the inhibition of 
oxidant production (a property of 14- and 15- 
membered-ring macrolides only), and the modulation 
of cytohne production. The underlying mechanisms 
are not known. In vivo these interactions of macrolides 
with phagocytes will be of major importance for 
therapeutic efficacy. Lastly, we have demonstrated that 
various 14- and 15-membered-ring macrolides pro- 
mote PMN exocytosis [36,37]. This is an attractive 
hypothesis to explain the bioactivity of these drugs in 
the case of microorganisms which lnhibit phagolyso- 
s o 4  fusion, providing that the drugs counteract this 
inhibitory effect of the microorganism. 
In conclusion, macrolides, an old family of anti- 
biotics, s t i l l  have many ‘tricks up their sleeve’. New 
microbial targets [38] and new clinical applications [39] 
should make these drugs a class of major importance in 
future anti-infective strategies. 
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